ETS1 Modulates Mitophagy via SENP2/HSPA8/FUNDC1 Axis in BPD

Study Background and Research Question

Bronchopulmonary dysplasia (BPD) is a severe chronic lung disorder predominantly affecting preterm infants, characterized by impaired alveolar development, persistent respiratory distress, and long-term pulmonary dysfunction. Despite advances in neonatal care, the incidence of BPD remains high, and current interventions largely address symptomatic relief rather than the underlying pathogenic mechanisms. Accumulating evidence implicates mitochondrial dysfunction and aberrant mitophagy—an autophagic process targeting damaged mitochondria—as central contributors to BPD pathogenesis. However, the precise molecular regulators orchestrating mitophagy in the context of BPD have not been fully elucidated.

In this context, the reference study (Yang et al., 2026) investigates the role of the transcription factor ETS1 in modulating mitochondrial autophagy within the developing lung, aiming to clarify the molecular axis by which ETS1 confers protection against BPD.

Key Innovation from the Reference Study

The core innovation of this research lies in identifying ETS1 as a transcriptional hub that mitigates mitochondrial damage-induced autophagy by targeting a specific molecular axis: SENP2/HSPA8/FUNDC1. ETS1 was demonstrated to suppress excessive mitophagy—thereby preserving alveolar structure—by promoting the transcription of SENP2. SENP2, a SUMO-specific protease, facilitates the deSUMOylation of FUNDC1, a mitophagy receptor, which in turn exposes the binding site for the chaperone protein HSPA8. This regulatory cascade fosters the degradation of FUNDC1, thus inhibiting overactive mitophagy. The work provides a mechanistic basis for targeting the ETS1-SENP2-HSPA8-FUNDC1 axis as a strategy to preserve mitochondrial and cellular homeostasis during lung development in adverse conditions such as hyperoxia.

Methods and Experimental Design Insights

The study utilized both in vitro and in vivo models of hyperoxia-induced BPD to dissect the molecular and cellular consequences of ETS1 modulation. Key experimental approaches included:

• Generation of BPD models by subjecting neonatal mice and cultured alveolar epithelial cells to hyperoxic environments, recapitulating clinical features of BPD.
• ETS1 overexpression and knockdown through genetic engineering to assess its role in lung development and mitophagy regulation.
• Assessment of mitochondrial damage and autophagic flux using electron microscopy, immunoblotting for autophagy markers, and quantification of mitochondrial function.
• Analysis of molecular interactions and post-translational modifications (e.g., FUNDC1 SUMOylation) using co-immunoprecipitation and SUMOylation assays.
• Functional rescue experiments, including SENP2 knockdown, to validate the specificity of the ETS1-SENP2-HSPA8-FUNDC1 pathway in mediating observed effects.

This multifaceted experimental design enabled the authors to establish causal relationships between ETS1 activity, the SENP2/HSPA8/FUNDC1 axis, and the physiological outcomes relevant to BPD.

Core Findings and Why They Matter

The study's main findings can be summarized as follows (Yang et al., 2026):

• ETS1 overexpression ameliorates BPD pathology: In hyperoxia-exposed models, increased ETS1 levels preserved alveolar number and improved lung structure, correlating with reduced mitophagy and mitigation of mitochondrial damage.
• SENP2 is an essential mediator: ETS1 upregulates SENP2, which removes SUMO1 modifications from FUNDC1, thus enabling HSPA8 binding and subsequent FUNDC1 degradation.
• Axis specificity confirmed: SENP2 knockdown reversed the protective effects of ETS1, reinstating excessive mitophagy and BPD-like pathology.
• Chaperone-mediated autophagy cross-talk: By regulating HSPA8 and FUNDC1, the study highlights a mechanistic intersection between mitophagy and chaperone-mediated autophagy research, providing new avenues for targeted therapeutic interventions.

These results have significant implications for the understanding of autophagy pathway modulation and lysosomal receptor regulation in developmental lung injury and related diseases.

Comparison with Existing Internal Articles

While the reference study focuses on transcriptional regulation of mitophagy in the context of BPD, several internal resources have explored tools and strategies for dissecting chaperone-mediated autophagy and related pathways in stem cell biology research. For instance, internal reviews such as "QX77: Molecular Chaperone Activator for Cutting-Edge Autophagy Research" and "QX77: Molecular Chaperone Activator for Advanced Autophagy Research" discuss the utility of QX77 as a molecular chaperone activator capable of upregulating LAMP2A and Rab11, thereby enabling precise experimental control over chaperone-mediated autophagy. These articles emphasize QX77's role in troubleshooting autophagic flux and supporting differentiation protocols in stem cell biology workflows.

In contrast to the genetic and transcriptional approaches highlighted in the Yang et al. study, QX77 represents a chemical biology tool that allows for the direct modulation of key autophagy regulators at the protein level. This distinction is important for researchers who require temporal and dose-dependent control over autophagy processes, supplementing insights gained from genetic models with actionable experimental interventions.

Limitations and Transferability

Although the findings from the reference study offer compelling mechanistic insights, several limitations should be considered:

• Model specificity: The primary evidence is derived from hyperoxia-induced BPD in mouse and cell models, which, while relevant, may not fully recapitulate the complexity of human neonatal BPD.
• Translational maturity: While the SENP2/HSPA8/FUNDC1 axis is validated in preclinical settings, its therapeutic potential in clinical BPD remains to be explored.
• Pathway specificity: The study centers on mitophagy, with limited exploration of broader chaperone-mediated autophagy networks or potential compensatory mechanisms in vivo.

Nonetheless, the molecular framework established by this work is likely transferable to other contexts where mitochondrial quality control and autophagy pathway modulation are central—such as stem cell maintenance, tissue regeneration, and other pulmonary or metabolic diseases.

Protocol Parameters

• Hyperoxia-induced BPD modeling: Neonatal mice exposed to ≥85% O₂ for 7–14 days recapitulate core features of BPD for mechanistic studies.
• ETS1 modulation: Overexpression or knockdown using recombinant adenoviral vectors or siRNA transfection; optimal dosing and timing as per experimental endpoints.
• Mitophagy assessment: Transmission electron microscopy and immunoblotting for LC3-II, FUNDC1, and HSPA8; recommended time points at 3, 7, and 14 days post-exposure.
• SENP2/FUNDC1 SUMOylation analysis: Co-immunoprecipitation and SUMOylation assays performed on lung tissue lysates or cultured cells after genetic manipulation.
• Chaperone-mediated autophagy manipulation: For chemical activation, compounds such as QX77 can be considered (see below for practical details).

Research Support Resources

For investigators seeking to experimentally modulate chaperone-mediated autophagy and lysosomal receptor regulation in cellular models, QX77 (SKU BA3596) is a molecular chaperone activator that upregulates LAMP2A and Rab11, offering a complementary approach to genetic techniques described in the reference paper. QX77 enables practical, temporal control of autophagy pathways and can be integrated into workflows investigating mitochondrial homeostasis, stem cell differentiation, and autophagy pathway modulation. As highlighted in recent internal reviews, QX77 is suitable for research applications requiring reproducible manipulation of autophagic flux and is provided by APExBIO for research use only.